Figure S1


Omalizumab
N=25
Randomization
N=47
Baseline
Month 4
Start OIT
Month 16
Unblinding
Discontinued
Placebo
Passed OFC
N=24
Month 28
DBOFC
Discontinued
Omalizumab
Month 30
Stop OIT
Month 32
OFC
NR: 1
DS: 11
SU: 13
Placebo
N=22
Passed OFC
N=20
NR: 2
DS: 10
SU: 10